Exclusion Criteria:~* Any medical or neurological condition other than AD that in the opinion of the
investigator could be a contributing cause of the participant's dementia (e.g., medication use, vitamin B12
deficiency, abnormal thyroid function, stroke or other cerebrovascular condition, diffuse Lewy body disease,
head trauma)~* History within the past 6 months or evidence of clinically significant psychiatric illness
(e.g., major depression, schizophrenia, or bipolar affective disorder)~* Diagnosis of a dementia-related
central nervous system (CNS) disease other than AD (e.g., Parkinson's Disease, Huntington's Disease,
frontotemporal dementia, multi-infarct dementia, dementia with Lewy bodies, normal pressure hydrocephalus)~*
Identification of other known cause of dementia or any other clinically significant contributing co-morbid
pathologies at screening magnetic resonance imaging (MRI), in the opinion of the investigator~* Participation
in any other drug, biologic, device, or clinical study or treatment with any investigational drug or approved
therapy for investigational use within 30 days (or 5 half lives, whichever is longer) prior to screening,
and/or participation in any other clinical study involving experimental medications for AD within the 60 days
(or 5 half lives, whichever is longer) prior to screening
